De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Pediatrix Medical Group Balans Gezondheid
Financiële gezondheid criteriumcontroles 3/6
Pediatrix Medical Group heeft een totaal eigen vermogen van $706.5M en een totale schuld van $630.4M, wat de schuld-eigenvermogensverhouding op 89.2% brengt. De totale activa en totale passiva bedragen respectievelijk $2.0B en $1.3B. De EBIT Pediatrix Medical Group is $152.4M waardoor de rentedekking 4.1 is. Het heeft contanten en kortetermijnbeleggingen van $133.2M.
Belangrijke informatie
89.2%
Verhouding schuld/eigen vermogen
US$630.37m
Schuld
| Rente dekkingsratio | 4.1x |
| Contant | US$133.20m |
| Aandelen | US$706.46m |
| Totaal verplichtingen | US$1.29b |
| Totaal activa | US$2.00b |
Recente financiële gezondheidsupdates
Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Jun 19
Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Nov 14Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Aug 09Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet
Apr 26Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Jan 12Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly
Sep 13Recent updates
We Like These Underlying Return On Capital Trends At Pediatrix Medical Group (NYSE:MD)
Sep 28Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified
Aug 07Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Jun 19Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger
May 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking
Mar 29Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors
Dec 25Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Nov 14Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?
Oct 13Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Aug 09Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold
Aug 08At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?
Jul 03The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing
Jun 08Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet
Apr 26Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?
Feb 20Pediatrix Medical Group Q4 2022 Earnings Preview
Feb 16Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Jan 12Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold
Dec 22Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing
Dec 20Pediatrix appoints James Swift as chief executive officer
Dec 15Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Nov 05Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M
Nov 03Pediatrix: These 5 Graphs Suggest It's A Buy
Sep 29Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly
Sep 13Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return
Aug 29Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Jul 27Pediatrix: Seeking 46% Return Objective As Speculative Buy
Jul 14MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jun 24MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet
May 25Return Trends At MEDNAX (NYSE:MD) Aren't Appealing
Apr 20MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 08MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly
Feb 15Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital
Jan 19Is MEDNAX, Inc. (NYSE:MD) Trading At A 40% Discount?
Nov 17These 4 Measures Indicate That MEDNAX (NYSE:MD) Is Using Debt Reasonably Well
Oct 23Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital
Oct 08Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $429.2M ) MD } overtreffen de korte termijn passiva ( $310.2M ).
Langlopende schulden: De kortetermijnactiva van MD ( $429.2M ) dekken de langetermijnschulden ( $978.7M ) niet.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 70.4% ) MD wordt als hoog beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van MD is de afgelopen 5 jaar gestegen van 76.3% naar 89.2%.
Schuldendekking: De schuld van MD wordt goed gedekt door de operationele kasstroom ( 20.8% ).
Rentedekking: De rentebetalingen op de schuld van MD worden goed gedekt door EBIT ( 4.1 x dekking).